Forbion Co-leads $54m Series A Financing in newly formed Gotham Therapeutics
Posted on October 11, 2018 in Forbion, Forbion highlight
Naarden, The Netherlands, and Munich, German, 10 October 2018 – Forbion, a leading European life sciences venture capital firm, today announces that it invested $15 million in the $54 million Series A financing in Gotham Therapeutics, a newly formed biotechnology company developing a novel drug class targeting RNA-modifying proteins.
